NUC-3373: Clinical Trials

3 trials of NUC-3373, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 2, Completed 1
Phase 12Completed 1, Terminated 1

Follow NUC-3373: new trials by email Literature Review of NUC-3373 trials Research Report on NUC-3373

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms
Phase 2TerminatedNuCana plc1802023-04-182025-09-12
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor
Phase 1 / Phase 2TerminatedNuCana plc192023-03-082026-07-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NUC-3373 + leucovorin, NUC-3373, NUFOX - Colorectal Cancer, Colorectal Neoplasms
Phase 1 / Phase 2CompletedNuCana plc1112018-10-052025-04-23

Conditions studied

Colonic Neoplasms (2)  ·  Colorectal Neoplasms (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Endometrial Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Melanoma (1)  ·  Mesothelioma, Malignant (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Stomach Neoplasms (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

NuCana plc (3)

Countries

United Kingdom (3)  ·  France (2)  ·  United States (2)  ·  Germany (1)  ·  Italy (1)  ·  Spain (1)

Top investigators

Elisabeth Oelmann, MD PhD (1)  ·  Elisabeth Oelmann, MD, PhD (1)

NIH funding

2017 (1)